Nuroflux

Stroke is a critical medical condition that claims the lives of 23 Australians per day, with this number expected to rise aligned with ageing populations. The current gold standard in stroke monitoring is CT scanning, however CT scans are limited to 24-hour windows to prevent excess exposure to radiation. There is no method of continuous monitoring for brain activity and blood flow between CT scans, allowing for sudden recurrence of stroke to go unnoticed even during treatment.

Every second counts for an oxygen-starved brain. This is why Health10x 2021 alumni nuroflux is developing a wearable device for the continuous monitoring of stroke patients, to fill the gap between CT scans and ensure secondary strokes do not go unnoticed. Nuroflux was born from this critical unmet need, bringing together multiple fields of medicine, engineering and commercial expertise to deliver real-time insights and mitigate brain injury and death.

The non-invasive wearable technology developed by nuroflux’s Sam van Bohemen is designed to continuously monitor stroke treatment and detect new signs of stroke. Sam van Bohemen has a neuroscience background and is currently completing a PhD in biomedical engineering. nuroflux is supported by advisors and experts in clinical care, engineering, commercialisation and market access to ensure impact for a global health context.

Health10x, nuroflux has collaborated with the Global Brain Health program at The George Institute with the aim to engage in clinical trials and further refine the wearable device.